Lauren Derstine1, Erik Soule2, Naudare Shabandi2, Zarina Arutyunova3, Chandana Lall2, Christopher Scuderi4, Jerry Matteo2. 1. University of Florida College of Medicine, Jacksonville, Florida, USA. 2. Department of Radiology, University of Florida Health, Jacksonville, Florida, USA. 3. Department of Pathology, University of Florida Health, Jacksonville, Florida, USA. 4. Department of Community Health and Family Medicine, University of Florida Health, Jacksonville, Florida, USA.
Abstract
BACKGROUND: Granular cell tumors (GCTs) or Abrikossoff's tumors are rare neoplasms known to originate from Schwann cells in the peripheral nervous system. These lesions are usually benign; malignancy only occurs in 1-2% of cases. Surgical resection is the traditional treatment method for GCTs, but it poses several risks and disadvantages related to the surgical incompatibility of the patient, the extended recovery time, and the chance of relapse. Cryoablation is becoming an increasingly favored method of treatment for tumors, both benign and malignant, due to its minimal invasiveness, natural analgesic properties, and ability to stimulate antitumor immunity. Cryoablation may contribute to the prevention of secondary and metastatic tumor growth in cases of malignancy by preserving tumor-associated antigen molecules for recognition by cell-mediated immunity. METHODS: This article describes a novel method for GCT treatment using cryoablation. This technique exposes tumor tissue to extreme cold temperatures, effectively destroying tumor cells by irreversibly compromising their plasma membranes. To our knowledge, this is the first report in the literature of cryoablative techniques being used for GCT. RESULTS: Cryoablation of this mass was successful with no complications. CT images during the procedure demonstrated circumferential coverage of the entire lesion with no injury to the surrounding tissues. CONCLUSION: Cryoablation can be used as an alternative to surgical intervention to treat malignant GCTs. This procedure is minimally invasive, less painful, and potentially effective in promoting antitumor immunity.
BACKGROUND: Granular cell tumors (GCTs) or Abrikossoff's tumors are rare neoplasms known to originate from Schwann cells in the peripheral nervous system. These lesions are usually benign; malignancy only occurs in 1-2% of cases. Surgical resection is the traditional treatment method for GCTs, but it poses several risks and disadvantages related to the surgical incompatibility of the patient, the extended recovery time, and the chance of relapse. Cryoablation is becoming an increasingly favored method of treatment for tumors, both benign and malignant, due to its minimal invasiveness, natural analgesic properties, and ability to stimulate antitumor immunity. Cryoablation may contribute to the prevention of secondary and metastatic tumor growth in cases of malignancy by preserving tumor-associated antigen molecules for recognition by cell-mediated immunity. METHODS: This article describes a novel method for GCT treatment using cryoablation. This technique exposes tumor tissue to extreme cold temperatures, effectively destroying tumor cells by irreversibly compromising their plasma membranes. To our knowledge, this is the first report in the literature of cryoablative techniques being used for GCT. RESULTS: Cryoablation of this mass was successful with no complications. CT images during the procedure demonstrated circumferential coverage of the entire lesion with no injury to the surrounding tissues. CONCLUSION: Cryoablation can be used as an alternative to surgical intervention to treat malignant GCTs. This procedure is minimally invasive, less painful, and potentially effective in promoting antitumor immunity.
Authors: Eric M Vikingstad; Gustaaf G de Ridder; Richard R Glisson; Diana M Cardona; Devon DiPalma; William C Eward; Brian E Brigman; Rendon C Nelson; Charles Y Kim Journal: J Vasc Interv Radiol Date: 2015-06-09 Impact factor: 3.464
Authors: J van der Maten; J L G Blaauwgeers; T G Sutedja; H B Kwa; P E Postmus; Sj Sc Wagenaar Journal: J Thorac Cardiovasc Surg Date: 2003-09 Impact factor: 5.209